Somaxon Pharmaceuticals (SOMX) Posts Q4 Loss of 21c/Share, Inline with the Street

March 8, 2012 4:24 PM EST Send to a Friend
Get Alerts SOMX Hot Sheet
Trade SOMX Now!
Join SI Premium – FREE
Somaxon Pharmaceuticals, Inc. (NASDAQ: SOMX) reported Q4 EPS of ($0.21), in-line with the analyst estimate of ($0.21). Revenue for the quarter came in at $3.9 million versus the consensus estimate of $4.42 million.

Lowered its FY12 total non-GAAP operating expenses to $15-$16 million.

For earnings history and earnings-related data on Somaxon Pharmaceuticals, Inc. (SOMX) click here.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Earnings

Related Entities

Earnings

Add Your Comment